NEW YORK (TheStreet) -- Geron (GERN) surged Thursday after the company announced the FDA had removed a partial clinical hold on the investigator-sponsored clinical trial of imetelstat in myelofibrosis (Myelofibrosis IST).
The FDA placed the hold in March 2014 because of safety concerns of hepatotoxicity in the clinical trials of imetelstat. The investigator, Dr. Ayalew Tefferi of the Mayo Clinic in Rochester, Minnesota, gave follow-up information on the reversibility of hepatotoxicity for all patients who received imetelstat in the trial, and the FDA informed him in a letter Wednesday that the trial could continue.
The stock was up 22.69% to $3.19 at 9:56 a.m. on Thursday.
Must Read: Warren Buffett's 25 Favorite Stocks